Survival Analyses of Patients With Metastatic Renal Cancer Treated With Targeted Therapy With or Without Cytoreductive Nephrectomy: A National Cancer Data Base Study [Urologic Oncology]
Conclusion
CN is performed in three of 10 patients with mRCC who are receiving TT. Several patient and sociodemographic characteristics were associated with receipt of CN. When feasible, CN may offer an OS benefit when combined with TT.
Source: Journal of Clinical Oncology - Category: Cancer & Oncology Authors: Hanna, Sun, Meyer, Nguyen, Pal, Chang, de Velasco, Trinh, Choueiri Tags: Surgery, Chemotherapy, Combined Modality Urologic Oncology Source Type: research
More News: Academia | Cancer | Cancer & Oncology | Carcinoma | Chemotherapy | Insurance | Kidney Cancer | Nephrectomy | Renal Cell Carcinoma | Study | Urology & Nephrology